Diamedica Stock Analysis

DMAC
 Stock
  

USD 1.24  0.04  3.12%   

The big decline in price over the last few months for Diamedica Therapeutics could raise concerns from investors as the firm is trading at a share price of 1.24 on 6,149 in volume. The company executives failed to add value to investors and position the firm supply of money to exploit market volatility in August. However, diversifying your holdings with Diamedica Therapeutics or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.19. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Diamedica Therapeutics partners.
Continue to Investing Opportunities.
  
The Diamedica Therapeutics stock analysis report makes it easy to digest most publicly released information about Diamedica Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Diamedica Stock analysis module also helps to analyze the Diamedica Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Diamedica Stock Analysis Notes

About 26.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.86. Some equities with similar Price to Book (P/B) outperform the market in the long run. Diamedica Therapeutics recorded a loss per share of 0.59. The entity had not issued any dividends in recent years. The firm had a split on the 15th of November 2018. DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Diamedica Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. To learn more about Diamedica Therapeutics call Rick Pauls at 763 612 6755 or check out https://www.diamedica.com.

Diamedica Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Diamedica Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Diamedica Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Diamedica Therapeutics generated a negative expected return over the last 90 days
Diamedica Therapeutics has high historical volatility and very poor performance
Diamedica Therapeutics may become a speculative penny stock
Diamedica Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 447.37 K. Net Loss for the year was (13.56 M) with profit before overhead, payroll, taxes, and interest of 500 K.
Diamedica Therapeutics currently holds about 38.44 M in cash with (12.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 26.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Acquisition by Daves Julie Vanorsdel of 140000 shares of Diamedica Therapeutics subject to Rule 16b-3

Diamedica Therapeutics Upcoming and Recent Events

Earnings reports are used by Diamedica Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Diamedica Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report9th of March 2022
Next Financial Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End9th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Diamedica Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Diamedica Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Diamedica Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Diamedica Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
10th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
12th of July 2022
Unclassified Corporate Event
View
6th of July 2022
Financial Statements and Exhibits. Other Events
View
29th of June 2022
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
27th of May 2022
Unclassified Corporate Event
View
25th of May 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
19th of May 2022
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
4th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Diamedica Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Diamedica Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Diamedica Therapeutics backward and forwards among themselves. Diamedica Therapeutics' institutional investor refers to the entity that pools money to purchase Diamedica Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Stonepine Capital Management LlcCommon Shares1.2 M2.4 M
Vanguard Group IncCommon Shares782.6 K1.6 M
Jacob Asset Management Of New York LlcCommon Shares238.5 K482 K
Geode Capital Management LlcCommon Shares177 K357 K
Northern Trust CorpCommon Shares101.7 K206 K
Blackrock IncCommon Shares66.7 K135 K
State Street CorpCommon Shares66.6 K135 K
Susquehanna International Group LlpCall Options59 K119 K
Susquehanna International Group LlpPut Options21.2 K43 K
Note, although Diamedica Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Diamedica Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 32.26 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Diamedica Therapeutics's market, we take the total number of its shares issued and multiply it by Diamedica Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (27.78) % which means that it has lost $27.78 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (46.74) %, meaning that it created substantial loss on money invested by shareholders. Diamedica Therapeutics management efficiency ratios could be used to measure how well diamedica therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 29th of September, Diamedica Therapeutics shows the mean deviation of 4.29. Diamedica Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Diamedica Therapeutics, which can be compared to its rivals. Please confirm Diamedica Therapeutics mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and information ratio to decide if Diamedica Therapeutics is priced favorably, providing market reflects its regular price of 1.24 per share. Given that Diamedica Therapeutics is a hitting penny stock territory we advise to closely look at its total risk alpha.

Diamedica Therapeutics Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Moving Average is predictive technique used to analyze Diamedica Therapeutics price data points by creating a series of averages of different subsets of Diamedica Therapeutics entire price series.
.

Diamedica Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Diamedica Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Diamedica Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Diamedica Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Daves Julie Vanorsdel over a week ago via Macroaxis 
Acquisition by Daves Julie Vanorsdel of 140000 shares of Diamedica Therapeutics subject to Rule 16b-3
Von Koch Thomas over two months ago via Macroaxis 
Purchase by Von Koch Thomas of 207974 shares of Diamedica Therapeutics
Giuffre Randall Michael over three months ago via Macroaxis 
Diamedica Therapeutics exotic insider transaction detected
Semba Charles Pauling over three months ago via Macroaxis 
Acquisition by Semba Charles Pauling of 13222 shares of Diamedica Therapeutics subject to Rule 16b-3
Cundari Dominic R over six months ago via Macroaxis 
Acquisition by Cundari Dominic R of 125000 shares of Diamedica Therapeutics subject to Rule 16b-3
Gruis Kirsten L over six months ago via Macroaxis 
Acquisition by Gruis Kirsten L of 160000 shares of Diamedica Therapeutics subject to Rule 16b-3
Burroughs Amy L over six months ago via Macroaxis 
Acquisition by Burroughs Amy L of 11182 shares of Diamedica Therapeutics subject to Rule 16b-3
Scott Kellen over six months ago via Macroaxis 
Purchase by Scott Kellen of 3000 shares of Diamedica Therapeutics
James Parsons over six months ago via Macroaxis 
Acquisition by James Parsons of 12950 shares of Diamedica Therapeutics subject to Rule 16b-3
Harry Alcorn over a year ago via Macroaxis 
Diamedica Therapeutics exotic insider transaction detected
Burroughs Amy L over a year ago via Macroaxis 
Purchase by Burroughs Amy L of 44950 shares of Diamedica Therapeutics
Pauls Dietrich John over a year ago via Macroaxis 
Purchase by Pauls Dietrich John of 5000 shares of Diamedica Therapeutics

Diamedica Therapeutics Technical and Predictive Indicators

Diamedica Therapeutics Forecast Models

Diamedica Therapeutics time-series forecasting models is one of many Diamedica Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Diamedica Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Diamedica Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Diamedica Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Diamedica shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Diamedica Therapeutics. By using and applying Diamedica Stock analysis, traders can create a robust methodology for identifying Diamedica entry and exit points for their positions.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Diamedica Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.

Current Diamedica Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Diamedica analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Diamedica analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
17.33Strong Buy3Odds
Diamedica Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Diamedica analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Diamedica stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Diamedica Therapeutics, talking to its executives and customers, or listening to Diamedica conference calls.
Diamedica Analyst Advice Details

Diamedica Stock Analysis Indicators

Diamedica Therapeutics stock analysis indicators help investors evaluate how Diamedica Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Diamedica Therapeutics shares will generate the highest return on investment. By understating and applying Diamedica Therapeutics stock analysis, traders can identify Diamedica Therapeutics position entry and exit signals to maximize returns.
Quick Ratio25.08
Fifty Two Week Low1.1500
Shares Short Prior Month53.62k
Average Daily Volume Last 10 Day80k
Average Daily Volume In Three Month142.17k
Shares Percent Shares Out0.11%
Short Percent Of Float0.12%
Forward Price Earnings-1.28
Float Shares17.41M
Fifty Two Week High4.8200
Enterprise Value To Ebitda0.46
Fifty Day Average1.5995
Two Hundred Day Average2.3839
Continue to Investing Opportunities. Note that the Diamedica Therapeutics information on this page should be used as a complementary analysis to other Diamedica Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for Diamedica Stock analysis

When running Diamedica Therapeutics price analysis, check to measure Diamedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diamedica Therapeutics is operating at the current time. Most of Diamedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of Diamedica Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Diamedica Therapeutics' price. Additionally, you may evaluate how the addition of Diamedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Is Diamedica Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Diamedica Therapeutics. If investors know Diamedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Diamedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Diamedica Therapeutics is measured differently than its book value, which is the value of Diamedica that is recorded on the company's balance sheet. Investors also form their own opinion of Diamedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Diamedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Diamedica Therapeutics' market value can be influenced by many factors that don't directly affect Diamedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Diamedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Diamedica Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Diamedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.